EMA Recommends Six New Medicines for Approval, Including for Metastatic Pancreatic Cancer and Type 2 Diabetes

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended six new medicines for approval following its October 2026 meeting. Among these, Rasonque (daraxonrasib) received a positive opinion for treating adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior treatment. Additionally, Foundayo (orforglipron), an oral GLP-1 medicine, was recommended for marketing authorization for weight management and type 2 diabetes.